BioTech Watch - Gilead Sciences, Inc (NASDAQ:GILD), Amgen, Celgene Corporation, Oncolytics Biotech

Birmingham, West Midlands -- (SBWIRE) -- 02/21/2013 -- Value Penny Stock key goal and commitment to our members is to provide you with exclusive newsletter that represents our reliability, and differentiates us from the other promotional newsletters! We pride ourselves in presenting picks that will make our followers money on a regular basis, as well as staying away from the stocks that are frequently being diluted.

Gilead Sciences, Inc (NASDAQ:GILD) ended lower by -0.40 points or -0.95% to complete the day at 41.88. The total number of shares changed hands during the day was 9.39 million. After opening at $42.51, the stock hit as high as $42.84. However, it traded between $21.91 and $43.04 over the last twelve months. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide.

Has GILD Found The Bottom and Ready To Move Up? Find Out Here

Amgen, Inc (NASDAQ:AMGN) closed yesterday at $84.65, a 0.62% increase. Around 6.38 million shares were traded, down from an-average trading volume of 6.82 million shares. The company is now valued at around $64.00 billion. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.

For How Long AMGN’s Gloss will Attract Investors? Find out via this report

Celgene Corporation (NASDAQ:CELG) moved -0.06 percent lower at $100.40 and traded between $100.39 and $103.69 after opening the day at $101.99. Its performance over the last five days remained 0.27%, which stands at 1.1% for a month. Going back further than one month, 1-year performance after recent close was 34.51%.Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe.

Will CELG Get Buyers Even After The Recent Rally? Find Out Here

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)’s shares down, declining -16.49 percent to close at $3.90. The stock is down around -0.51% this year and -22.16% for the last 12 months. Around 4.63 million shares changed hands yesterday, higher from an-average trading volume of 624,930.00 shares. Oncolytics Biotech Inc., a biotechnology company, focuses on the development of oncolytic viruses as potential cancers therapeutics.

Why Should Investors Buy ONCY After the Recent Fall? Just Go Here and Find Out

About Value Penny Stocks
Value Penny Stocks was made by Two Active traders Steve and Wilson whom have make a platform for trader in order to provide traders #1 Penny Stock Newsletter which actually give your value to your money and make your portfolio full of Profits. We concentrate on value small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves in understanding the overall market situations, and use this knowledge in order to gain a better perception during our stock picking decisions.

Disclaimer
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.